Memphis Pharmaceuticals is one of Egypt's oldest drug makers, now controlled by the state and quietly profitable. Its latest audited year shows a sharp jump in earnings, even as the company remains a small player in a large market. Full nameMemphis Pharmaceutical & Chemical Industries Tickers / exchangeMPCI.EGX — Egyptian Exchange (EGX) HeadquartersCairo, Egypt SectorPharmaceuticals EmployeesNot published in available sources Market valueNot published in available sources Yearly sales (FY ended 30 June 2025)EGP 1,507,800,000 — about US$28.8 million Net profit (FY2025)EGP 505,279,620 — about US$9.65 million Net margin (our calculation)33.5% …
Company Intelligence — Institutional Access
This dossier is part of our Company Intelligence database.
Full profiles, exchange dossiers and the regional intelligence briefs are available to institutional subscribers. Professional from US$490/year, Corporate US$1,450, Institutional US$3,900.
See institutional access →Already a subscriber? Log in.
Part of LatAm Company Intelligence
This company profile belongs to The Rio Times' research on every listed company and exchange in Latin America and the Caribbean. Browse the full intelligence hub →
Not ready to buy? Try Company Intelligence free for 14 days →
Editorial responsibility: Matthias Camenzind, Editor-in-Chief · Editorial standards · Report an error
Read More from The Rio Times
The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →